A total of 124 patients who had survived at least 2 years after allogeneic bone marrow transplantation (BMT) were studied. Serum was collected at least once yearly. IgG antibodies were determined by enzyme-linked immunosorbent assay for measles and mumps. Rubella antibodies were analyzed by radial hemolysis. Antibody levels were interpreted as representing immunity, seronegativity, or seropositivity, but with uncertain immunity. The median follow-up of the patients was 6.5 years (range, 2 to 13.5 years). The calculated probabilities of being immune to measles at 3,5, and 7 years from BMT were 47%. 279'0. and 2090. respectively. The corresponding probabilities for mumps were 37%. 12%. and 6%. respectively; and for rubella, 4790, 33%. and 28%, respectively. The probabilities for being seronegative for measles,
LLOGENEIC BONE MARROW transplantation (BMT)
has now been used for treatment of hematologic malignancies and different nonmalignant hematologic and metabolic disorders for more than 20 years. Because of the increased number of long-term survivors, the studies of late side-effects of BMT are becoming increasingly important. One area for study is immunity to different infectious agents during follow-up. The B-cell-mediated immune reconstitution after BMT has been extensively studied during the first years after BMT. It has been shown that it is depressed for years, particularly in patients with chronic graft-versus-host disease (GVHD). [1] [2] [3] [4] We have previously analyzed the immunity to measles, mumps, and rubella sequentially during the first 4 years after allogeneic BMT. Our data indicated the probability for a patient to remain immune continuously decreased during follow-up. However, we were not able to analyze whether this loss of immunity would continue until most patients would have become seronegative or stabilize so that patients immune at approximately 4 years after allogeneic BMT would remain immune during longer f~llow-up.~ The aim of this study was to attempt to identify factors influencing the immune status to measles, mumps, and rubella during extended follow-up after BMT.
A PATIENTS AND METHODS

Patients.
A total of 124 consecutive patients who had survived and who were free from relapse at least 2 years after allogeneic BMT were studied. The median follow-up of the patients was 6.5 years (range, 2 to 13.5 years). Data from 57 of these patients with a follow-up of less than 4 years were published earlier? The BMT procedure was performed as previously described!-* Patient characteristics are shown in Table 1 . The study was approved by the ethical committee of the Karolinska Institute at Huddinge Hospital (Huddinge, Sweden).
Serology. Serum samples were collected once yearly. Pretransplant sera from the patients and the donors were analyzed when available. Ideally, all sera from all patients should have been analyzed by the same technique at the same time. Unfortunately, many of the early sera analyzed in our previous study were not available for reanalysis. Therefore, to obtain data from as many patients as possible for as long a follow-up as possible, results from the earlier IgG antibody determinations were also used in this study. Also, Blood, Vol 84, No 2 (July 15). 1994: pp 657-663 mumps, and rubella at 5 years after BMT were 60%. 73%. and 52%. respectively. When compared with those patients who had experienced previous natural measles disease (P c .05), the only factor that was important for immunity to measles after BMT was whether the patient had been immunized before BMT. There was no influence of donor seropositivity on the probability of becoming seronegative to mumps during follow-up. We conclude that most allogeneic patients will become seronegative to measles, mumps, and rubella during follow-up. Therefore, long-term B-cell memory function is not maintained, regardless of the immune status of the donor. 0 1994 by The American Society of Hematology.
because the serologic techniques vaned over time, the last serum sample from each patient included in the earlier study, in whom follow-up continued, was reanalyzed in this study, and the results were used as a reference value for later sera. The results from sera that were analyzed both in the earlier study and this study were in agreement concerning the patient's immune status to measles, mumps, and rubella in all cases. Therefore, we feel that the analysis of the combined data is acceptable, despite the fact that different serologic techniques were used at different times. However, so as not to overestimate the loss of immunity or development of seronegativity, results from the testing of 2 subsequent samples were used to decide immune status when available. These 2 subsequent samples were in agreement in the immune status classification in more than 95% of the patients.
Serologic techniques. IgG antibodies against measles and mumps were determined by enzyme-linked immunosorbent assay (ELISA) in both parts of the study. For measles and mumps, an ELISA titer of greater than 1,000 was interpreted as representing immunity, a titer of 100 to 1 , OOO was interpreted as seropositive but not immune, and a titer of less than 100 was interpreted as seronegative. In the first part of the study, IgG antibodies to rubella were determined by ELISA? In the second part of the study, antibodies were analyzed by radial hemolysis, and the results were interpreted as immune, seropositive but not immune, or seronegative, according to known positive and negative control sera.'
Statistics. Proportions of patients remaining immune and becoming seronegative were calculated according to the Kaplan-Meier product limit estimation technique. Patients were censored from the 658 LJUNGMAN ET AL Abbreviations: TBI, total body irradiation; ATG, antithymocyte globulin.
analysis at the time of measles, mumps, and rubella (MMR) vaccination after BMT. Altogether, 48 patients were reimmunized with MMR vaccine, usually at 2 years after BMT. ' Univariate analysis of risk factors was performed by the log-rank test. A Cox regression model was used for analyzing the influences of diagnosis, GVHD prophylaxis, acute and chronic GVHD, conditioning regimen, donor, patient age, and patient history, ie, whether the patient had experienced natural measles disease or had been immunized on immunologic status after transplant. For the calculations of immune status for patients with natural disease or for those having previously been immunized, patients born before 1972, when measles immunization was introduced in Sweden, were presumed to have had natural disease. Accordingly, patients born after 1982, when measles immunization was recommended to Swedish children, were presumed to have been immunized unless otherwise stated in the patient's chart. For all but 5 patients born between 1972 and 1982, data concerning immunization or natural disease were present in the charts. These 5 patients were included in the calculations in the immunized group so as not to overestimate the loss of immunity in patients who had had natural disease.
RESULTS
Serologic status to measles before BMT.
A total of 117 of 124 (94%) patients were immune to measles pretransplant, and an additional 6 patients were seropositive but not immune; therefore, 99% of the patients had antibodies to measles. Sera were tested from 79 donors; 73 of 79 (92%) of the donors were immune, and 6 were seronegative to measles before BMT.
Seronegativity and immunity to measles after BMT. The calculated probability for becoming seronegative during follow-up after BMT is shown in Fig 1. In univariate analyses, lower patient age and whether the patient had been immunized to measles before BMT instead of having had a natural measles disease were significant risk factors for seronegativity after BMT. Diagnosis (malignant v nonmalignant), conditioning regimen (TB1 v other), or GVHD prophylaxis did not influence seronegativity after BMT. Because age and vaccination before BMT did strongly correlate with each other, two multivariate models were constructed. The first model included age, vaccination before BMT, acute GVHD, chronic GVHD, and diagnosis. In this model, no factor had a significant impact on seronegativity after BMT, but vaccination before BMT had a risk ratio of 2.0 (95% confidence interval, 0.9 to 4.7). The second model was constructed without age as a variable, and the results are shown in Table 2 . There was no difference in the results when only the 1 19 patients for whom immunization status was known were included in the model (data not shown).
Vaccination before BMT was the only significant risk factor in multivariate analysis for losing immunity to measles after BMT (data not shown). The Kaplan-Meier probabilities for immunity in patients who were immunized before BMT or who had natural measles disease are shown in Fig 2. We also tried to analyze the influence of donor and recipient serologic status before BMT on the serologic status after BMT (Table 3 ). However, because there was a difference in serologic status of the donor and the recipient in only 7 cases, no detailed analysis could be performed. One patient who was seronegative before BMT and who had a seropositive donor was seropositive at 1 year after BMT, but at 2 years, no antibodies against measles could be detected. Six seropositive patients had seronegative donors. Of these six patients, 4 became seronegative during follow-up.
Immunity to mumps before UMT. A total of 77 (66%) of 117 tested patients were seropositive, and 64 (85%) of 75 tested donors were immune to mumps before BMT. For 7 patients, the serologic status was unknown. Only seropositive patients or seronegative patients who had seropositive donors were included in the subsequent calculations. One seronegative patient with a seronegative donor seroconverted during follow-up without being immunized, presumably representing a primary mumps infection.
Immunity and seronegativity to mumps after UMT. The calculated probabilities of being immune to mumps at 3, 5 , and 7 years after BMT were 37%, 12%, and 6%, respectively. The calculated probabilities for being seronegative for mumps at 3 , 5, and 7 years after BMT were 57%, 73%, and 91 %, respectively. The calculated probabilities for being seronegative after BMT according to the different donor and recipient serologic status combinations before BMT are shown in Fig 3. Immunity to rubella before BMT. A total of 107 of 117 (91%) tested patients and 51 of 62 tested donors (82%) were seropositive to rubella before BMT. Only seropositive patients or seronegative patients who had seropositive donors were included in the subsequent calculations. No seronegative patient with seronegative donor seroconverted during follow-up without being immunized.
immunity and seronegativity to rubella after BMT. The calculated probabilities of being immune to rubella at 3, 5, and 7 years after BMT were 47%, 36%, and 28%, respectively. The calculated probability for being seronegative for rubella after BMT is shown in Fig 4. 
DISCUSSION
Allogeneic BMT involves eradication of the recipient immune system and the replacement of it with the immune system of the BM donor's. Whether the transferred immune system also can retain its immunologic memory has not been studied conclusively on a long-term basis. Wahren et all0 studied the transfer of donor and persistence of recipient immunity by analysis of donor and recipient pairs who were discrepant in their immune status for the antigens studied." They showed that transfer of donor immunity does occur but that also recipient immunity can be retained for at least 12 months after BMT. Furthermore, it was found that both the donor-and the recipient-specific immunity in the discrepant donorhecipient situation seemed to have a finite duration after allogeneic BMT. In a similarly designed study, Lum et a13 confirmed the transfer of specific donor imm~nity.~ Moreover, they found that many transplanted patients retained their immunity to measles, tetanus, and diphtheria during more than 2 years of follow-up. However, this study analyzed the situation at one time point and, therefore, did We chose to analyze the immunity to measles, mumps and rubella for the purpose of this study, because these viruses are usually not latent or persistent in the infected individual and, thus, presence of specific antibodies a long time after BMT could be expected to represent either transferred or persistent immunologic memory. A majority of the patients became seronegative to measles, mumps, and rubella within 5 years of the transplant regardless of the serologic status of the donor. Before BMT, the frequencies of seropositivity to measles in both patients and donors were greater than 90%; that is comparable with frequencies found in normal adult populations (eg, our hospital staff).".'* Thus, these results show that long-term immunologic memory usually is not transferred from the BM donor to the allogeneic BM" recipient.
The only recognizable risk factor in this study for becoming seronegative was previous immunization in contrast to having natural measles disease. This risk factor for development of seronegativity to measles was previously found by Pauksen et all3 in autologous BMT patients. Furthermore, several studies of BMT patients have shown loss of immunization immunity to other antigens such as tetanus toxoid, polio virus, and pneumococcal poly~accaride.'~"' It is likely that natural measles disease more strongly induces immunologic memory than does immunization with the attenuated measles vaccine. This is supported by the reported increased rate of loss of immunity in vaccinated healthy individuals compared with that of individuals who have had natural measles disease." Risk factors for loss of immunity in the study by Matson et a1 were vaccination during the first year of life and a time from vaccination to study of at least 13 years. It is likely that BMT accelerates the rate of immunity loss in previously immunized children because the median age when seronegativity was detected in our previously immunized group was only 6.5 years.
Months after BMT
In patients who had experienced natural measles disease, the difference in the rate of loss of immunity between allogeneic BMT patients and other groups of immunosuppressed patients is even more marked. Whereas greater than 50% of our patients were already seronegative at 4 years after BMT, Pauksen et a1 found that greater than 90 of the patients remained immune to measles at 3 years after autologous BMT. Furthermore, Kemper et a1 found that greater than 95% of human immunodeficiency virus-infected patients remained seropositive to measles." An explanation for this finding in allogeneic BMT recipients was suggested by Storek et al through studies of quantitative and phenotypic studies of B-cell reconstitution. They showed that, in patients without chronic GVHD, the pattern resembles the pattern in normal infants." In contrast, the pattern in patients with chronic GVHD was markedly abnormal. We have previously found that a single dose of tetanus toxoid or inactivated polio virus vaccine is not enough to booster immunity in most patients but that a full primo-immunization schedule is needed.14.'' This would indicate that the B cells that reconstitute the immune system are recruited from stem cells rather than from mature memory cells. Therefore, our findings of the defect in long-term B-cell memory after BMT is consistent with the finding that the newly regenerated B cells in the patients without chronic GVHD need antigenic stimulation to mediate very long-term persistence of specific antibodies after BMT. It has been suggested that, by immunizing the donors before the BMT, the possibility to retain B-cell immunity can be improved.21*22 However, none of these studies have analyzed patients during long-term follow-up and, therefore, the question can not be answered at this time.
Chronic GVHD was not found to be a risk factor for losing immunity in our study, which is in contrast to the findings by Lum et al?3 This could be explained by different rates or severity in chronic GVHD in the two studies. Most of our patients had only limited chronic GVHD. Another explanation could be the design of the studies.
Our longitudinal design cleady shows that the patients without chronic GVHD also lose immunity during extended follow-up. We were also unable to find any influence of T-cell depletion on the immune status after BM", which has been found previo~sly?~ However, the number of T-cell-depleted patients in our study was small.
The dynamics of the transfer of donor immunity during short-and long-term follow-up could be analyzed through the rates of loss of immunity in the different donor and recipient combinations. From our data, it seems clear that transfer of donor immunity contributes to production of specific antibodies early after allogeneic BMT. However, there was no appreciable difference in the rate of loss of immunity between the different donor and recipient serologic combinations, indicating a finite life span of the transferred B cells.
Our data clearly indicate that very few patients remain immune to reinfection with these viruses for longer than 10 years after transplant. Two thirds of the patients had already lost immunity to all three viruses at 5 years after transplant. This rate of loss of specific immunity is substantially quicker than what can be expected in normal individuals, particularly for patients who have previously experienced natural disease where immunity usually is life-long. It is unknown if, after allogeneic BMT, long-term nonimmune survivors would be at risk for developing a severe measles infection. Infections with measles regularly caused severe and sometimes lethal infections in immunocompromised children before widespread immunization against measles was intr~duced.'~-'~ Recently, there have been cases of disseminated measles infection in patients with acquired immunodeficiency syndrome.'* It could be argued that, because the number of described cases in BMT patients is low considering that measles virus has circulated in different areas of the world during the era of BMT, the risk for severe disease is also low, particularly in long-term survivors whose immunosuppression at that time after BMT is mild. However, we believe it is of practical importance for the physician taking care of these patients to be aware of the fact that many patients will be vulnerable to measles infection because of a reappearance of measles in several countries.
We conclude that, during extended follow-up after allogeneic BMT, most patients will become seronegative to measles, mumps, and rubella showing that specific immune reconstitution to nonlatent infectious agents does not result in a duration of immunity comparable with that of normal individuals. This finding has implications for the practical management of long-term survivors after allogeneic BMT in that patients must be assumed to be at an increased risk for infections with many infectious agents. To protect BMT patients against this increased risk for infections, reimmunization programs should be considered, particularly for tetanus toxoid, diphtheria toxoid, and inactivated polio virus vaccine. For each patient, the need for reimmunization against measles must be balanced against the risk for infection from the community. 
